Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FavorAx: Axitinib in favorable risk mRCC
NCT02700568Phase 2Completed
- Start
- Jan 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib in metastatic renal cell carcinoma (mRCC). Started Jan 2016; status: completed.
02
Drugs
axitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02700568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02700568.